Eva Obermayr, Thomas Mohr, Eva Schuster, Elena Ioana Braicu, Eliane Taube, Jalid Sehouli, Ignace Vergote, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Philipp Harter, Pauline Wimberger, Florence Joly-Lobbedez, Sven Mahner, Ute Martha Moll, Nicole Concin, Robert Zeillinger
Disease progression is a major problem in ovarian cancer. There are very few treatment options for patients with platinum-resistant ovarian cancer (PROC), and therefore, these patients have a particularly poor prognosis. The aim of the present study was to identify markers for monitoring the response of 123 PROC patients enrolled in the Phase I/II GANNET53 clinical trial, which evaluated the efficacy of Ganetespib in combination with standard chemotherapy versus standard chemotherapy alone. In total, 474 blood samples were collected, comprising baseline samples taken before the first administration of the study drugs and serial samples taken during treatment until further disease progression (PD)...
April 27, 2024: International Journal of Cancer. Journal International du Cancer